Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
NeuroLeukin
- Development stage
- Preclinical
- Lead developer
- Therapeutic Solutions International
- Modality
- Small Molecules, Nanoparticles → Drug Delivery Systems
- Administration
- Intranasal
01
Overview
**NeuroLeukin** is a preclinical intranasal combination product from Campbell Neurosciences for depression and suicide risk. It combines autologous platelet-rich plasma with NanoStilbene, a patented pterostilbene delivery system, and is intended to increase brain-derived neurotrophic factor-mediated neurotrophic signaling. The proposed regimen is once-daily intranasal administration for one week.
- Other names
- NeuroLeukin
Beyond the preview
Go deeper on NeuroLeukin.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on NeuroLeukin.